Aims: Our purpose was to make an experimental assessment of the elements of creativity and the features of schizotypy in patients with bipolar disorder, compared with healthy control subjects and to investigate the effect of an acute affective episode (depressed or manic) and the features of schizotypy on the measurements of creativity. Methods: Forty patients with bipolar disorder, and 48 age- and gender-matched control subjects were studied. For the assessment of creativity the Revised Art Scale and the ‘inventiveness’ part of the Berlin Intelligence Structure Test (BIS) were used. The Oxford-Liverpool Inventory of Feelings and Experiences was applied for estimation of schizotypy. Results: The bipolar patients did not differ on the RAS scale from the control subjects but obtained significantly higher scores on the BIS-total as well as on the verbal part of the test. Their scores on the BIS scale during depression were significantly lower than in remission. The bipolar patients obtained significantly higher scores on all dimensions of schizotypy compared with the controls. Conclusions: These results confirm previous data showing higher scores on some creativity scales in bipolar patients compared with healthy subjects. They also corroborate a relationship between the features of schizotypy and creativity scores in bipolar patients.

Keywords:
Bipolar disorder, Creativity, Barron-Welsh Art Scale, Revised Art Scale, Berlin Intelligence Test, Schizotypy, Oxford-Liverpool Inventory of Feelings and Experiences, Mania, Depression, Remission
1.
Andreasen NC: Creativity and mental illness: prevalence rates in writers and their first-degree relatives. Am J Psychiatry 1987;144:1288–1292.
2.
Post F: Creativity and psychopathology: a study of 291 world-famous men. Br J Psychiatry 1994;165:22–34.
3.
Ludwig AM: Mental illness and creative activity in female writers. Am J Psychiatry 1994;151:1650–1656.
4.
Jamison KR: Manic-depressive illness and creativity. Sci Am 1995;272:62–67.
5.
Richards R, Kinney DK, Lunde I, Benet M, Merzel AP: Creativity in manic-depressives, cyclothymes, their normal relatives, and control subjects. J Abnorm Psychol 1988;97:281–288.
6.
Santosa CM, Strong CM, Nowakowska C, Wang PW, Rennicke CM, Ketter TA: Enhanced creativity in bipolar disorder patients: a controlled study. J Affect Disord 2007;100:31–39.
7.
Strong CM, Nowakowska C, Santosa CM, Wang PW, Kraemer HC, Ketter TA: Temperament-creativity relationships in mood disorder patients, healthy controls and highly creative individuals. J Affect Disord 2007;100:41–48.
8.
Schuldberg D: Eysenck Personality Questionnaire scales and paper-and-pencil tests related to creativity. Psychol Rep 2005;97:180–182.
9.
Burch GS, Pavelis C, Hemsley DR, Corr PJ: Schizotypy and creativity in visual artists. Br J Psychol 2006;97:177–190.
10.
Nelson B, Rawlings D: Relating schizotypy and personality to the phenomenology of creativity. Schizophr Bull 2010;36:388–399.
11.
Chapman LJ, Chapman JP, Numbers JS, Edell WS, Carpenter BN, Beckfield D: Impulsive nonconformity as a trait contributing to the prediction of psychotic-like and schizotypal symptoms. J Nerv Ment Dis 1984;172:681–191.
12.
Heron J, Jones I, Williams J, Owen MJ, Craddock N, Jones LA: Self-reported schizotypy and bipolar disorder: demonstration of a lack of specificity of the Kings Schizotypy Questionnaire. Schizophr Res 2003;65:153–158.
13.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
14.
Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429–435.
15.
Welsh GS: Preliminary Manual, the Welsh Figure Preference Test (rev ed). Palo Alto, Consulting Psychologists Press, 1959.
16.
Welsh GS, Gough HB, Hall WB, Bradley P: Manual for the Barron-Welsh Art Scale. Mind Garden, 2005.
17.
Barron F, Welsh GS: Artistic perception as a possible factor in personality style: its measurement by a figure preference test. J Psychol 1952;33:199–203.
18.
Jäger AO, Süss HM, Beauducel A: Berliner Intelligenzstruktur-Test: Form 4. Hogrefe, Göttingen, 1997.
19.
Reuter M, Roth S, Holve K, Hennig J: Indentification of first candidate genes for creativity: a pilot study. Brain Res 2006;1069:190–197.
20.
Mason O, Linnney Y, Claridge G: Short scales for measuring schizotypy. Schizophr Res 2005;78:293–296.
21.
Flaherty AW: Frontotemporal and dopaminergic control of idea generation and creative drive. J Comp Neurol 2005;493:147–153.
22.
Schuldberg D, French C, Stone BL, Heberle J: Creativity and schizotypal traits: creativity test scores and perceptual aberration, magical ideation, and impulsive nonconformity. J Nerv Ment Dis 1988;176:648–657.
23.
Kems JG: Positive schizotypy and emotion processing. J Abnorm Psychol 2005;114:392–401.
24.
Eysenck HJ, Furnham A: Personality and the Barron-Welsh Art Scale. Percept Mot Skills 1993;76:837–838.
25.
Miller GF, Tal IR: Schizotypy versus openness and intelligence as predictors of creativity. Schizophr Res 2007;93:317–324.
26.
Krysanski V, Ferraro FR: Creativity, unique designs, and schizotypy in a nonclinical sample. Psychol Rep 2007;101:273–274.
27.
Welsh GS: Gifted adolescents: A Handbook of Test Results. Greensboro, Prediction Press, 1969.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.